Ahmedabad, Feb 13: Torrent Pharmaceuticals Limited today announced its financial results for the third quarter of FY 26.
Key Highlights for Q3 FY26:
Revenue at Rs. 3,303 crores, up by 18% YoY
Op. EBITDA* at Rs.1,088 crores, up by 19% YoY
Op. EBITDA margin* at 33%; Gross Margin: 76%
Net Profit after tax at Rs. 635 crores, up by 26% YoY.
Country-wise performance:
India:
India revenues at Rs 1,798 crores were up 14%
As per AIOCD PharmaTrac secondary market data, IPM growth for the quarter was 10%.
Continued volume outperformance over IPM in chronic and sub-chronic therapies led by Cardiac, Gastro, and Diabetes (OAD) segments
For 9M FY26, revenues were Rs 5,430 crores, up by 12%.
Brazil:
Brazil revenues at Rs 371 crores, were up by 27%.
Constant currency revenues, at R$ 224 million, were up by 10%.
As per IQVIA, Torrent grew at 13% vs market growth of 7%; growth was aided by the performance of top brands & recent launches.
Torrent has 60 products under ANVISA review.
For 9M FY26, revenues were Rs 907 crores, up by 21% (Constant currency revenue: R$ 564 million, up by 13%).
United States:
US business revenues at Rs 321 crores, were up by 19%.
Constant currency revenues at $36 million, were up by 12% compared to the same period in the previous year. Recent launches have achieved target market shares.
For 9M FY26, revenues were Rs 967 crores, up by 21% (Constant currency revenue: $111 million up by 16%).
Germany:
Germany revenues at Rs 304 crores, were up by 8%.
Constant currency revenues at EUR 29 million, were down by 6%.
Growth continued to be impacted due to supply disruption at a third party supplier.
For 9M FY26, revenues were Rs 916 crores, up by 7% (Constant currency revenue: EUR 91 million, down by 3%).
About Torrent Pharmaceuticals Ltd:
Torrent Pharma, with annual revenues of more than Rs 11,500 crores, is the flagship Company of the Torrent Group, with group revenues of ~Rs 45,000 crores.
Post JB Pharma acquisition it is ranked 5th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS), Pain Management and Cosmo-Dermatology.
